Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% vs TRAVASOL 5.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis, providing essential and non-essential nitrogen sources for anabolism in patients unable to tolerate oral or enteral nutrition.
Travasol 5.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting metabolic functions in parenteral nutrition.
Intravenous infusion of 250-500 mL/day (8.75-17.5 g amino acids) as a component of parenteral nutrition; rate up to 125 mL/hour; titrate based on metabolic response.
500 mL of 5.5% amino acid solution intravenously over 2-4 hours daily, titrated to nitrogen balance and metabolic tolerance.
None Documented
None Documented
Terminal elimination half-life of individual amino acids ranges from 10 to 30 minutes for most, with glutamine and arginine slightly longer (30–45 min). No defined half-life for the mixture; clinically, steady-state achieved in 2–3 hours with continuous infusion.
Not applicable as individual amino acids have variable half-lives (minutes to hours). TRAVASOL is a mixture; the clinical context is continuous infusion to maintain plasma levels.
Renal: 95% of infused amino acids are reabsorbed; excess amino acids are deaminated and urea is excreted renally. Fecal/Biliary: negligible (<1%).
Amino acids in TRAVASOL 5.5% are metabolized and nitrogen waste is excreted primarily via renal elimination (as urea, >90% of nitrogen). Fecal elimination is negligible (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution